6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial

CONTEXT Survival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years of androgen suppression therapy (AST), but long-term AST is associated with many adverse events. OBJECTIVE To assess the survival benefit of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2004-08, Vol.292 (7), p.821-827
Hauptverfasser:	D'Amico, Anthony V, Manola, Judith, Loffredo, Marian, Renshaw, Andrew A, DellaCroce, Alyssa, Kantoff, Philip W
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - blood Adenocarcinoma - drug therapy Adenocarcinoma - radiotherapy Aged Aged, 80 and over Androgen Antagonists - therapeutic use Androgens Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Flutamide - therapeutic use General aspects Goserelin - therapeutic use Gynecology. Andrology. Obstetrics Humans Leuprolide - therapeutic use Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases Proportional Hazards Models Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Radiation Radiotherapy, Conformal Survival Analysis Therapy Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!